- Home
- OBE vs XOMA Comparison
OBE vs XOMA Comparison
Compare OBE & XOMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OBE
- XOMA
- Stock Information
- Founded
- OBE 1979
- XOMA 1981
- Country
- OBE Canada
- XOMA United States
- Employees
- OBE N/A
- XOMA N/A
- Industry
- OBE Oil & Gas Production
- XOMA Biotechnology: Pharmaceutical Preparations
- Sector
- OBE Energy
- XOMA Health Care
- Exchange
- OBE Nasdaq
- XOMA Nasdaq
- Market Cap
- OBE 391.9M
- XOMA 330.2M
- IPO Year
- OBE N/A
- XOMA N/A
- Fundamental
- Price
- OBE $6.01
- XOMA $37.42
- Analyst Decision
- OBE Buy
- XOMA Strong Buy
- Analyst Count
- OBE 2
- XOMA 2
- Target Price
- OBE $11.50
- XOMA $69.50
- AVG Volume (30 Days)
- OBE 236.1K
- XOMA 56.8K
- Earning Date
- OBE 10-30-2025
- XOMA 11-06-2025
- Dividend Yield
- OBE N/A
- XOMA N/A
- EPS Growth
- OBE N/A
- XOMA N/A
- EPS
- OBE N/A
- XOMA N/A
- Revenue
- OBE $508,849,882.00
- XOMA $44,952,000.00
- Revenue This Year
- OBE N/A
- XOMA $82.30
- Revenue Next Year
- OBE N/A
- XOMA $12.59
- P/E Ratio
- OBE N/A
- XOMA N/A
- Revenue Growth
- OBE 1.49
- XOMA 194.98
- 52 Week Low
- OBE $3.88
- XOMA $18.35
- 52 Week High
- OBE $6.53
- XOMA $38.00
- Technical
- Relative Strength Index (RSI)
- OBE 52.32
- XOMA 74.02
- Support Level
- OBE $5.87
- XOMA $33.59
- Resistance Level
- OBE $6.25
- XOMA $38.00
- Average True Range (ATR)
- OBE 0.20
- XOMA 1.69
- MACD
- OBE -0.01
- XOMA 0.16
- Stochastic Oscillator
- OBE 39.00
- XOMA 90.32
About OBE Obsidian Energy Ltd.
Obsidian Energy Ltd is an intermediate-sized oil and gas producer with strategic assets in Alberta. It operates in a single reporting segment that is exploration, development, and holding an interest in oil and natural gas properties and related production infrastructure in the Western Canada Sedimentary Basin. The company generates the majority of the revenue from the Crude oil sale.
About XOMA XOMA Corporation
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.